People · Operator
Named in public records as an officer, director or promoter · active 2019–2026 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nuvation Bio Inc. | — | Pharmaceuticals | Series D+ | $275.3M | $9.7B | 2019 |
| TheRas, Inc. | — | Biotechnology | Series D+ | $200.0M | $2.3B | 2024 |
| Caldera Therapeutics, Inc. | — | Biotechnology | Series B | $37.5M | $139.0M | 2026 |
Michelle Doig at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michelle Doig on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Aaron Royston | 1 | 7 |
| Frank McCormick | 1 | 7 |
| Claudio Nessi | 1 | 5 |
| Raymond Kelleher | 1 | 4 |
| Michael Gladstone | 1 | 3 |
| Kathryn E. Falberg | 1 | 3 |
| Kim Blickenstaff | 1 | 3 |
| Neil Kumar | 1 | 3 |
| Praveen Tipirneni | 1 | 2 |
| Robert Bazemore | 1 | 2 |
| W. Anthony Vernon | 1 | 2 |
| Daniel Anthony Welch | 1 | 1 |
| Xiaodi Su | 1 | 1 |
| Idan Elmelech | 1 | 1 |
| Pedro Beltran | 1 | 1 |
| Eli Wallace | 1 | 1 |
| David Hung, M.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.